Skye Bioscience, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
SKYE$0.84+21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations for the (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| For the Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating expenses | ||
| Research and development | $7,935,680 | $7,197,257 |
| General and administrative | 4,738,686 | 4,562,305 |
| Total operating expenses | 12,674,366 | 11,759,562 |
| Operating loss | (12,674,366) | (11,759,562) |
| Other (income) expense | ||
| Interest expense | 2,199 | 1,452 |
| Interest and other income, net | (169,615) | (619,054) |
| Other (income) expense | 2,411 | (40,641) |
| Total other (income) expense, net | (165,005) | (658,243) |
| Loss before income taxes | (12,509,361) | (11,101,319) |
| Provision for income taxes | — | 2,000 |
| Net loss | $(12,509,361) | $(11,103,319) |
| Loss per common share: | ||
| Basic | $(0.32) | $(0.28) |
| Diluted | $(0.32) | $(0.28) |
| Weighted average shares of common stock outstanding used to compute loss per share: | ||
| Basic | 39,681,465 | 39,651,888 |
| Diluted | 39,681,465 | 39,651,888 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.